Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 20.81
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Hybio Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of therapeutic peptides API and polypeptide drugs in China and internationally. The company provides liraglutide, semaglutide and exenatide for diabetes; terlipressin, desmopressin and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix and atosiban for obstetrics and gynecology, etc; customized peptides; working...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued
Data is available to registered users only
